A new study raises the intriguing possibility that drugs prescribed to lower cholesterol may be effective against macular degeneration, a blinding eye disease. Researchers at Washington University School of Medicine in St. Louis have found that age-related macular degeneration, the leading cause of vision loss in Americans over 50, shares a common link with atherosclerosis.
[More]
Targeting cholesterol metabolism in the eye might help prevent a severe form of age-related macular degeneration (AMD), one of the most common causes of blindness in older Americans, according to indications in a study in mice, which was supported by the National Institutes of Health.
[More]
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.
[More]
Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing.
[More]
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes.
[More]
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.
[More]
Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. Researchers at Ludwig-Maximilians-Universitaet in Munich have now identified a microRNA that plays a prominent role in the process, and offers a promising target for new therapies.
[More]
UCLA researchers have genetically engineered tomatoes to produce a peptide that mimics the actions of good cholesterol when consumed.
[More]
A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.
[More]
Doses of medicine 100,000 times smaller than the diameter of a human hair prevent the tissue damage associated with atherosclerosis and other chronic diseases in mice.
[More]
The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation treatment," which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse.
[More]
While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke.
[More]
A research team led by Robert Nagele, PhD, of the New Jersey Institute for Successful Aging (NJISA) at the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine, has demonstrated that the anti-atherosclerosis drug darapladib can significantly reduce leaks in the blood brain barrier.
[More]
Like nearly 4.6 million Americans, ancient hunter-gatherers also suffered from clogged arteries, revealing that the plaque build-up causing blood clots, heart attacks and strokes is not just a result of fatty diets or couch potato habits, according to new research in the journal The Lancet.
[More]
A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.
[More]
Patients diagnosed with post-traumatic stress disorder (PTSD) have a significantly higher risk of developing insulin resistance and metabolic syndrome, placing them at greater risk for heart disease and diabetes, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session. Researchers say public health interventions are urgently needed to prevent PTSD-related metabolic disorder at its early, reversible stage.
[More]
Heart attack rates have spiked in Greece since the start of the country's financial crisis, especially among women and residents older than 45, according to a study of patient records being presented at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Kidney failure affects 25 million individuals in the U.S. and many more throughout the world. Loss of kidney function means the majority of these patients must undergo dialysis treatments to remove excess fluids and waste products. Although dialysis therapy coupled with medication has improved the life expectancy for people with kidney failure, for unknown reasons, patients' risk of sudden heart failure and death remains 10 to 20 times greater than average.
[More]
New research provides early evidence that 'good' cholesterol may possess anti-aneurysm forming properties. In laboratory-based investigations, scientists found that increased levels of high-density lipoproteins (HDL), the so-called good cholesterol, blocked the development of aneurysms - dangerous 'ballooning' in the wall of a blood vessel - in the body's largest artery, the aorta.
[More]
New research from Rice University, Baylor College of Medicine (BCM) and the Puget Sound Blood Center (PSBC) has revealed how stresses of flow in the small blood vessels of the heart and brain could cause a common protein to change shape and form dangerous blood clots.
[More]